{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T05:07:01Z","timestamp":1768108021356,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,7]],"date-time":"2015-10-07T00:00:00Z","timestamp":1444176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007903","name":"Bloodwise","doi-asserted-by":"crossref","award":["12053"],"award-info":[{"award-number":["12053"]}],"id":[{"id":"10.13039\/501100007903","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Wellcome trust strategic funds and EPSRC Knowledge Transfer Account","award":["R\/134366-11-5"],"award-info":[{"award-number":["R\/134366-11-5"]}]},{"name":"University of Sheffield IIKE Proof of Concept Scheme","award":["138635"],"award-info":[{"award-number":["138635"]}]}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.bone.2015.10.004","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T13:48:41Z","timestamp":1444830521000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Osteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods"],"prefix":"10.1016","volume":"83","author":[{"given":"H.R.","family":"Evans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Karmakharm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.E.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fellows","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.D.","family":"Huggins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Richmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.D.","family":"Chantry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20 Pt 2","key":"10.1016\/j.bone.2015.10.004_bb0005","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.bone.2015.10.004_bb0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/bmb\/ldu016","article-title":"Myeloma bone disease: pathogenesis, current treatments and future targets","volume":"111","author":"Walker","year":"2014","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.bone.2015.10.004_bb0015","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM197411142912001","article-title":"Evidence for the secretion of an osteoclast stimulating factor in myeloma","volume":"291","author":"Mundy","year":"1974","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2015.10.004_bb0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nm1519","article-title":"NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF","volume":"13","author":"Park","year":"2007","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.bone.2015.10.004_bb0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1034\/j.1600-0609.2000.90074.x","article-title":"Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma","volume":"64","author":"Abildgaard","year":"2000","journal-title":"Eur. J. Haematol."},{"issue":"9","key":"10.1016\/j.bone.2015.10.004_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068103","article-title":"Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice","volume":"8","author":"Gregory","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bone.2015.10.004_bb0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2141.2011.08573.x","article-title":"Guidelines for the diagnosis and management of multiple myeloma 2011","volume":"154","author":"Bird","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"Suppl. 3","key":"10.1016\/j.bone.2015.10.004_bb0040","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdu103","article-title":"Bone health in cancer patients: ESMO Clinical Practice Guidelines","volume":"25","author":"Coleman","year":"2014","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol.\/ESMO"},{"issue":"2","key":"10.1016\/j.bone.2015.10.004_bb0045","doi-asserted-by":"crossref","first-page":"609","DOI":"10.4049\/jimmunol.122.2.609","article-title":"Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL\/KaLwRij mice","volume":"122","author":"Radl","year":"1979","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.bone.2015.10.004_bb0050","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/bjc.1997.409","article-title":"Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL\/KaLwRij mouse","volume":"76","author":"Vanderkerken","year":"1997","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.bone.2015.10.004_bb0055","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood.V96.5.1953","article-title":"Cell\u2013cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity","volume":"96","author":"Michigami","year":"2000","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bone.2015.10.004_bb0060","first-page":"6689","article-title":"Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID\/NOD in vivo model: biologic and clinical implications","volume":"63","author":"Mitsiades","year":"2003","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bone.2015.10.004_bb0065","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/blood.V95.3.1056.003k26_1056_1065","article-title":"Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice","volume":"95","author":"Pilarski","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bone.2015.10.004_bb0070","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2005-01-0373","article-title":"A clinically relevant SCID-hu in vivo model of human multiple myeloma","volume":"106","author":"Tassone","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bone.2015.10.004_bb0075","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1182\/blood.V94.10.3576.422k01_3576_3582","article-title":"The proliferative potential of myeloma plasma cells manifest in the SCID-hu host","volume":"94","author":"Yaccoby","year":"1999","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bone.2015.10.004_bb0080","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1182\/blood-2002-03-0939","article-title":"Antimyeloma efficacy of thalidomide in the SCID-hu model","volume":"100","author":"Yaccoby","year":"2002","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.bone.2015.10.004_bb0085","doi-asserted-by":"crossref","first-page":"10287","DOI":"10.1073\/pnas.1401337111","article-title":"Engineered nanomedicine for myeloma and bone microenvironment targeting","volume":"111","author":"Swami","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bone.2015.10.004_bb0090","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21310","article-title":"The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo","volume":"84","author":"Pennisi","year":"2009","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.bone.2015.10.004_bb0095","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bone.2015.10.004_bb0100","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/sj.leu.2403513","article-title":"The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells","volume":"18","author":"Yata","year":"2004","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bone.2015.10.004_bb0105","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bbrc.2003.11.120","article-title":"Establishment of a new model of human multiple myeloma using NOD\/SCID\/gammac(null) (NOG) mice","volume":"313","author":"Miyakawa","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.bone.2015.10.004_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079939","article-title":"Intratibial injection of human multiple myeloma cells in NOD\/SCID IL-2Rgamma(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies","volume":"8","author":"Schueler","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bone.2015.10.004_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119546","article-title":"NOD\/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease","volume":"10","author":"Lawson","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bone.2015.10.004_bb0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.bone.2015.10.004_bb0125","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1172\/JCI200420369","article-title":"Novel targeted deregulation of c-Myc cooperates with Bcl-X(L) to cause plasma cell neoplasms in mice","volume":"113","author":"Cheung","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.bone.2015.10.004_bb0130","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ccr.2007.02.015","article-title":"The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis","volume":"11","author":"Carrasco","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bone.2015.10.004_bb0135","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/1471-2407-8-228","article-title":"Imagable 4T1 model for the study of late stage breast cancer","volume":"8","author":"Tao","year":"2008","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.bone.2015.10.004_bb0140","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1172\/JCI3523","article-title":"TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development","volume":"103","author":"Yin","year":"1999","journal-title":"J. Clin. Invest."},{"issue":"2003","key":"10.1016\/j.bone.2015.10.004_bb0145","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreases osteolysis, tumour burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2015.10.004_bb0150","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1359\/jbmr.081104","article-title":"Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma","volume":"24","author":"Heath","year":"2009","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2015.10.004_bb0155","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/0008-5472.CAN-10-2868","article-title":"LOXL2-mediated matrix remodeling in metastasis and mammary gland involution","volume":"71","author":"Barker","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bone.2015.10.004_bb0160","series-title":"First International Symposium on 3d Data Processing Visualization and Transmission","first-page":"428","article-title":"Filling holes in complex surfaces using volumetric diffusion","author":"Davis","year":"2002"},{"key":"10.1016\/j.bone.2015.10.004_bb0165","series-title":"Scale Space and Variational Methods in Computer Vision. Lecture Notes in Computer Science","first-page":"62","article-title":"Volumetric nonlinear anisotropic diffusion on GPUs","volume":"6667","author":"Schwarzkopf","year":"2012"},{"issue":"2","key":"10.1016\/j.bone.2015.10.004_bb0170","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2015.10.004_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003188","article-title":"Bisphosphonates in multiple myeloma","volume":"3","author":"Djulbegovic","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.bone.2015.10.004_bb0180","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"9757","key":"10.1016\/j.bone.2015.10.004_bb0185","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bone.2015.10.004_bb0190","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.canlet.2007.07.007","article-title":"Bisphosphonates in cancer therapy","volume":"257","author":"Stresing","year":"2007","journal-title":"Cancer Lett."},{"issue":"3 Suppl","key":"10.1016\/j.bone.2015.10.004_bb0195","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.11128","article-title":"Antitumor effects of bisphosphonates","volume":"97","author":"Green","year":"2003","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.bone.2015.10.004_bb0200","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-08-4472","article-title":"Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma","volume":"69","author":"Deleu","year":"2009","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.bone.2015.10.004_bb0205","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/jbmr.142","article-title":"Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo","volume":"25","author":"Chantry","year":"2010","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.bone.2015.10.004_bb0210","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.bone.2015.10.004_bb0215","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/bjh.12007","article-title":"The role of imaging techniques in the management of multiple myeloma","volume":"159","author":"Zamagni","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2015.10.004_bb0220","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/583439","article-title":"Multiple myeloma: a review of imaging features and radiological techniques","author":"Healy","year":"2011","journal-title":"Bone Marrow Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328215003671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328215003671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T20:13:21Z","timestamp":1718136801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328215003671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":44,"alternative-id":["S8756328215003671"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2015.10.004","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2015.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}